Kusajili – Clinical trials directory

Result of your search per sponsor: Algeta ASA, Oslo, Norway

Man Max 99 years
Algeta ASA, Oslo, Norway Update Il y a 4 ans

A double-blind dose-response phase II, multicentre study of radium-223 (Alpharadrin ™) for the palliation of painful bone metastases in hormone refractory prostate cancer patients The primary objective of this study is to investigate whether there is a dose-response relationship for radium-223 in patients with painful bone metastases secondary to prostate carcinoma regarding th...

Country None
organs None
Specialty None

unknown

More information